[{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"2","companyTruncated":"Dewpoint Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dewpoint Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Dewpoint Therapeutics \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Dewpoint Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Dewpoint Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Dewpoint Therapeutics","amount2":0.75,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0.75,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Dewpoint Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Chemify","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Dewpoint Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Dewpoint Therapeutics \/ Dewpoint Therapeutics"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"ALS Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Condensate Modifying Drug","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint Therapeutics \/ ALS Association"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Target ALS Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"C-mods-based Therapy","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Target ALS Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint Therapeutics \/ Target ALS Foundation"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Dewpoint Therapeutics","amount2":0.41999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"2","companyTruncated":"Dewpoint Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"DPTX3186","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Dewpoint Therapeutics","amount2":0.47999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.47999999999999998,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Dewpoint Therapeutics \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"ConcertAI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"DPTX3186","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ ConcertAI","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint Therapeutics \/ ConcertAI"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"DPTX3496","moa":"CTNNB","graph1":"Oncology","graph2":"Preclinical","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dewpoint Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Dewpoint Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Dewpoint Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          NextGen Biomed
                          Not Confirmed
                          NextGen Biomed
                          Not Confirmed

                          Details : DPTX3496 is an oral, small molecule condensate modulator targeting beta catenin to address Wnt-driven colorectal cancer (CRC), triple-negative breast cancer (TNBC), and non-small cell lung cancer

                          Product Name : DPTX3496

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 29, 2025

                          Lead Product(s) : DPTX3496

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          NextGen Biomed
                          Not Confirmed
                          NextGen Biomed
                          Not Confirmed

                          Details : The partnership aims to advance Dewpoint's preclinical product DPTX3186 a c-mod that inhibits beta-catenin oncogenic function. It is being evaluated for the treatment of cancers.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 12, 2024

                          Lead Product(s) : DPTX3186

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : ConcertAI

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          NextGen Biomed
                          Not Confirmed
                          NextGen Biomed
                          Not Confirmed

                          Details : The collaboration of Dewpoint with MTPC to advance Dewpoint’s novel TDP-43 small molecule condensate modulator (c-mod) for the treatment of amyotrophic lateral sclerosis.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 04, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery

                          Sponsor : Mitsubishi Tanabe Pharma

                          Deal Size : $480.0 million

                          Deal Type : Collaboration

                          blank

                          04

                          NextGen Biomed
                          Not Confirmed
                          NextGen Biomed
                          Not Confirmed

                          Details : DPTX3186 is a c-mod that acts through a novel MOA to sequester beta-catenin into nuclear depot condensates. It is being evaluated for Wnt-driven colorectal cancer, and gastrointestinal cancer.

                          Product Name : DPTX3186

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 28, 2024

                          Lead Product(s) : DPTX3186

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          NextGen Biomed
                          Not Confirmed
                          NextGen Biomed
                          Not Confirmed

                          Details : Bayer obtains global license to develop and commercialize disease-modifying treatment specifically for dilated cardiomyopathy (DCM) patients characterized by specific mutations

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 24, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Discovery

                          Sponsor : Bayer AG

                          Deal Size : $424.0 million

                          Deal Type : Licensing Agreement

                          blank

                          06

                          NextGen Biomed
                          Not Confirmed
                          NextGen Biomed
                          Not Confirmed

                          Details : The grant will support the in vivo development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in amyotrophic lateral sclerosis.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 26, 2024

                          Lead Product(s) : C-mods-based Therapy

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Target ALS Foundation

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          07

                          NextGen Biomed
                          Not Confirmed
                          NextGen Biomed
                          Not Confirmed

                          Details : The grant will support the development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in amyotrophic lateral sclerosis animal model.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 16, 2024

                          Lead Product(s) : Condensate Modifying Drug

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : ALS Association

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          08

                          NextGen Biomed
                          Not Confirmed
                          NextGen Biomed
                          Not Confirmed

                          Details : Under the partnership, Chemify and Dewpoint will develop a suite of digitally discovered and automatically synthesized novel molecules on Chemify's programmable chemistry platform against condensate targets of interest in Dewpoint's oncology and neurodeg...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 12, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Chemify

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          09

                          NextGen Biomed
                          Not Confirmed
                          NextGen Biomed
                          Not Confirmed

                          Details : The partnership brings together Novo Nordisk's global leadership in treating diabetes and metabolic diseases with Dewpoint's groundbreaking discovery and AI technology platform to identify modulators of biomolecular condensates.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 22, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Discovery Platform

                          Sponsor : Novo Nordisk

                          Deal Size : $745.0 million

                          Deal Type : Partnership

                          blank

                          10

                          NextGen Biomed
                          Not Confirmed
                          NextGen Biomed
                          Not Confirmed

                          Details : Dewpoint Therapeutics and Pfizer will collaborate for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 06, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Sponsor : Pfizer Inc

                          Deal Size : $239.0 million

                          Deal Type : Collaboration

                          blank